Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Surufatinib in Second-line Advanced or Metastatic Cholangiocarcinoma
NCT05697237Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Fragment-Derived Small Molecules, Orthosteric Ligands
01
Overview
Open-label, single-arm trial of camrelizumab and surufatinib in cholangiocarcinoma (CCA), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Progression-Free Survival at 6 months. Status: unknown.
02
Drugs
camrelizumabsurufatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05697237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05697237.